We then treated BT-549 and MDA-MB-231 breast cancer cell lines with C646, a CREBBP inhibitor, and found that the protein level of NUCB2 decreased in a dose-dependent manner with increasing concentrations of C646 (Fig. 1F. Additional file 1: Fig. S1D). Here, NUCB2 is linked to breast carcinoma.